



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
Silver Spring, MD 20993

NDA 21462/S-052

**SUPPLEMENT APPROVAL**

Eli Lilly and Company  
Attention: Paul Orth, Pharm.D  
Manager, Global Regulatory Affairs-US  
Lilly Corporate Center, Drop Code 2543  
Indianapolis, IN 46285

Dear Dr. Orth:

Please refer to your Supplemental New Drug Application (sNDA) dated and received October 20, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Alimta<sup>®</sup> (pemetrexed for injection).

This Prior Approval supplemental new drug application provides for revisions to the carton and container labels for the drug product, to change the term “Single-Use Vial” to “Single -Dose Vial”.

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the patient package insert) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes

approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and immediate container labels that are identical to enclosed carton and immediate container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 21462/S-052.**” Approval of this submission by FDA is not required before the labeling is used.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Adijat Abass-Fasuyi, Regulatory Business Process Manager, at (301) 796 - 3609.

Sincerely,

*{See appended electronic signature page}*

Ramesh Raghavachari, Ph.D.  
Chief, Branch I  
Division of Post-Marketing Activities I  
Office of Lifecycle Drug Products  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research

Enclosure:  
Carton and Container Labeling



Ramesh  
Raghavachari

Date: 4/17/2018 02:27:17PM

GUID: 502d0913000029f375128b0de8c50020